Just caught something interesting about NTR back in January - Morgan Stanley flipped their call from Equal-Weight to Overweight on Nutrien. But here's the weird part: their price target is sitting at $49.10, which would be like 26% downside from where it was trading then. So the upgrade doesn't exactly scream bullish, you know?

Looking at the fund moves on NTR, there's been some shuffling. Royal Bank of Canada bumped up their stake to 7.19% of the company, though they actually reduced their overall portfolio weight in it. Bank of Montreal also increased shares but cut their allocation. Meanwhile, Arrowstreet Capital was one of the few actually adding more weight to their NTR position last quarter.

The put/call ratio sitting at 2.42 suggests people are still hedging downside risk on this one. Revenue projections look decent at 35 billion with growth expected, but the consensus seems cautious. Mixed signals on NTR - institutions are juggling positions but not exactly rushing in.